Patient and Provider Characteristics Associated with First-Line Treatment of HR+/HER2– Metastatic Breast Cancer Patients in the U.S.

In a joint study with Concerto HealthAI and Pfizer, presented at the 37th Annual Miami Breast Cancer Conference, researchers sought to understand both patient and provider characteristics associated with the decision of first-line treatment regimens for patients with metastatic breast cancer (mBC) in the U.S.

Structured electronic medical record (EMR) data from Concerto's Definitive Oncology Dataset was used to analyze patient-level variables:  first-line (1L) treatment regimen, sex, age, race/ethnicity, menopausal status, hormonal status, performance status (ECOG), weighted comorbidity index, length of 1L regimen, de-novo or recurrent metastatic, time from first breast cancer diagnosis to first mBC diagnosis, time from treatment index date to present, prior treatment history.

Concerto scientists also accessed external provider data to include these provider and practice-level variables in the analysis: region; urban or rural; size; type (academic vs. community; OCM or not).

Three first-line therapies emerged: CDK4/6i-containing therapy, endocrine therapy, and chemotherapy. The study concluded that despite CDK4/6i-containing therapy is recommended as 1L in NCCN guidelines, there is still significant use of the other two therapies as first-line. Both provider-level and patient-level factors are associated with these treatment choices for HR+/HER2– mBC patients in the real-world setting.

eCongress DownloadTreatment distribution-Pfizer mBC1957